TB-500 is a synthetic peptide fragment derived from Thymosin Beta-4 (Tβ4), a naturally occurring protein found in virtually all human and animal cells. While Thymosin Beta-4 is a 44-amino-acid protein, TB-500 corresponds to its core actin-binding domain — the sequence responsible for many of Tβ4’s most studied biological activities. For Australian researchers sourcing tissue-repair reference compounds, TB-500 is one of the most extensively studied synthetic peptides in musculoskeletal and wound-healing models.
This guide covers TB-500’s molecular identity, proposed mechanisms, current research findings, and how it compares to BPC-157 — for laboratory reference purposes only.
What Is TB-500?
TB-500 is a 43-amino-acid synthetic fragment of Thymosin Beta-4, sharing the same core active region (Ac-SDKP — N-Acetyl-Seryl-Aspartyl-Lysyl-Proline) believed to drive the parent molecule’s most important biological activities. The fragment was developed to provide a more tractable research tool than the full Tβ4 protein while retaining the key functional domain.
Molecular Identity
- Full name: Thymosin Beta-4 Fragment
- Molecular weight: ~4963 Da
- Active core: Ac-SDKP (N-Acetyl-Seryl-Aspartyl-Lysyl-Proline)
- Source protein: Thymosin Beta-4 (Tβ4), a ubiquitous eukaryotic actin-sequestering protein
Mechanism of Action
Actin Sequestration and Cell Motility
TB-500’s primary proposed mechanism centres on binding monomeric G-actin (globular actin) and maintaining a polymerisation-ready pool. Actin polymerisation into F-actin (filamentous actin) is fundamental to cell motility, shape change, and tissue remodelling. By sequestering G-actin, TB-500 is hypothesised to regulate the rate and direction of cell movement — particularly relevant in wound healing models where migrating keratinocytes and fibroblasts drive tissue closure.
Ac-SDKP: The Active Tetrapeptide
The tetrapeptide Ac-SDKP represents the minimally active region of the Tβ4 molecule and has demonstrated biological activities in its own right, including:
- Anti-inflammatory effects via NF-κB pathway modulation
- Anti-fibrotic activity — inhibition of TGF-β1-mediated fibrosis in cardiac and renal models
- Angiogenic effects via endothelial cell stimulation
- Haematopoietic stem cell proliferation regulation
Angiogenesis
Multiple preclinical studies have demonstrated TB-500’s capacity to promote new blood vessel formation, involving upregulation of VEGF-related signalling and direct endothelial cell stimulation through the Ac-SDKP motif. This angiogenic activity is proposed to support both wound closure and musculoskeletal tissue repair by improving local perfusion.
Key Research Findings (2024–2026)
A comprehensive scoping review published in Applied Sciences (MDPI, 2025) evaluated the available literature on TB-500 and Thymosin Beta-4 in tissue healing and regeneration. The review covered musculoskeletal repair, wound healing, cardiovascular tissue, and neurological models, finding consistent preclinical signals across tissue types.
A 2025 study published in Materials Today Bio used exosomes from Thymosin Beta-4-overexpressing adipose-derived stem cells in a hydrogel matrix, demonstrating accelerated diabetic wound closure in a murine model — illustrating continued research interest in TB-500’s downstream pathways.
Strongest Research Signals by Tissue Type
- Musculoskeletal and tendon repair — consistent preclinical signals in animal ligament and muscle injury models
- Wound healing — cell migration and wound closure studies in dermal models
- Cardiac tissue — Ac-SDKP’s anti-fibrotic mechanism studied in cardiac fibrosis models
- Corneal and ocular repair — Tβ4 and TB-500 studied in ocular surface injury models
- Neuroprotection — early-stage research into neuroinflammation and recovery models
TB-500 vs BPC-157: Research Differentiation
These two peptides are frequently co-studied and are sometimes combined in animal injury models, but they have distinct molecular mechanisms and primary research targets:
| Parameter | TB-500 | BPC-157 |
|---|---|---|
| Origin | Thymosin Beta-4 fragment | Gastric protein sequence |
| Chain length | 43 amino acids | 15 amino acids |
| Primary mechanism | Actin sequestration (G-actin binding), Ac-SDKP | VEGFR2 activation, eNOS / NO modulation |
| Primary research focus | Musculoskeletal, cardiac, corneal, wound closure | GI mucosa, tendon, vascular signalling |
| Anti-fibrotic signal | Strong (cardiac/renal models) | Limited data |
| Human data | No completed human trials | No completed human trials |
See also: BPC-157 Research Guide →
Regulatory and Research Status
As of 2026, TB-500 has no completed human efficacy or pharmacokinetic trials published in the peer-reviewed literature. In the United States, it was classified as an FDA 503A Category 2 bulk drug substance in April 2026, prohibiting its use in compounded medications. In Australia, TB-500 is not scheduled under the TGA Poisons Standard and is available for legitimate laboratory and research use.
Storage and Handling
Lyophilised TB-500 should be stored at −20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 4 weeks. Do not vortex. Aliquot before freezing to avoid repeat freeze–thaw cycles. For full protocols see the peptide storage guide →
Browse TB-500 research compounds →
Frequently Asked Questions
What is TB-500 and how does it differ from Thymosin Beta-4?
TB-500 is a synthetic 43-amino-acid fragment of the naturally occurring Thymosin Beta-4 (Tβ4) protein. It contains the core Ac-SDKP active sequence believed to drive most of Tβ4’s biological activity. The full Tβ4 protein is 44 amino acids; TB-500 is the isolated active fragment used as a more tractable research tool.
What is the Ac-SDKP sequence and why is it important in research?
Ac-SDKP (N-Acetyl-Seryl-Aspartyl-Lysyl-Proline) is the minimally active tetrapeptide within Thymosin Beta-4 and TB-500. Research has shown it possesses independent biological activity including anti-inflammatory effects via NF-κB modulation, anti-fibrotic activity (TGF-β1 inhibition in cardiac models), angiogenic effects, and haematopoietic stem cell regulation.
Is TB-500 legal to purchase for research in Australia?
Yes. TB-500 is not scheduled under the TGA Poisons Standard and is legally available in Australia for laboratory and research use only. It is not approved for human or veterinary therapeutic use.
How does TB-500 compare to BPC-157 in research models?
TB-500 and BPC-157 have distinct mechanisms: TB-500 operates primarily via G-actin sequestration and Ac-SDKP signalling, with strongest research signals in musculoskeletal, cardiac, and wound models. BPC-157 works via VEGFR2 activation and NO modulation, with primary research interest in GI mucosa and vascular signalling. They are frequently combined in animal musculoskeletal injury studies as complementary rather than redundant compounds.
How should TB-500 be stored in a research setting?
Lyophilised TB-500 should be stored at −20°C, protected from light and moisture, for up to 24 months. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 4 weeks. Aliquot before freezing to avoid repeat freeze–thaw cycles.
For laboratory and research use only. Not for human or veterinary consumption. Nothing in this article constitutes medical advice.
